<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309734</url>
  </required_header>
  <id_info>
    <org_study_id>AT-01C-001</org_study_id>
    <secondary_id>2019-004997-24</secondary_id>
    <nct_id>NCT04309734</nct_id>
  </id_info>
  <brief_title>Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects</brief_title>
  <official_title>A Phase I/IIa Study Assessing AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics
      (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral
      activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in
      HCV-infected subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Part A is randomized, double-blind. Part B is open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Through Day 6 for subjects in Part A</time_frame>
    <description>Number of subjects experiencing treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Through 4 weeks after end of treatment for subjects in Part B</time_frame>
    <description>Number of subjects experiencing treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral Activity of AT-777 and AT-527</measure>
    <time_frame>Through 2 weeks of treatment for subjects in Part B</time_frame>
    <description>Number of subjects who achieve plasma HCV RNA &lt; lower limit of quantitation (LLOQ) and target not detected (TND)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AT-777 maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1 for subjects in Part A</time_frame>
    <description>PK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AT-777 area under the concentration-time curve (AUC)</measure>
    <time_frame>Day 1 for subjects in Part A</time_frame>
    <description>PK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving sustained virologic response (SVR)</measure>
    <time_frame>12 weeks after end of treatment for subjects in Part B</time_frame>
    <description>SVR defined as the HCV RNA &lt; lower limit of quantitation (LLOQ) at 12 weeks after end of treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C Virus Infection</condition>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Part A - 60 mg AT-777 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 120 mg AT-777 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-777</intervention_name>
    <description>Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.</description>
    <arm_group_label>Part A - 120 mg AT-777 single dose</arm_group_label>
    <arm_group_label>Part A - 60 mg AT-777 single dose</arm_group_label>
    <arm_group_label>Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally, as one or two placebo capsules, depending on the arm.</description>
    <arm_group_label>Part A - Placebo single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.</description>
    <arm_group_label>Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All:

          -  Body mass index (BMI) of 18-35 kg/m2

          -  Must agree to use protocol-specified methods of contraception

          -  Negative pregnancy test

          -  Willing to comply with the study requirements and to provide written informed consent

        Additional for Part A:

        -18-55 years of age

        Additional for Part B:

          -  18-65 years of age

          -  HCV genotype 1, 2 or 3

          -  Documented history compatible with chronic hepatitis C

          -  HCV RNA â‰¥ 10,000 IU/mL at Screening

        Exclusion Criteria:

        All:

          -  Pregnant or breastfeeding

          -  Abuse of alcohol or drugs

          -  Use of other investigational drugs within 30 days of dosing

          -  Other clinically significant medical conditions

        Additional for Part B:

          -  Prior exposure to any HCV NS5A inhibitor

          -  Cirrhosis

          -  Co-infection with hepatitis B virus or HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Jian Zhou</last_name>
    <role>Study Director</role>
    <affiliation>Atea Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Jian Zhou, PhD</last_name>
    <phone>857-284-8946</phone>
    <email>Zhou.XJ@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

